ARGATROBAN 1 MG — DIN 02548968
ARGATROBAN : 1 MG · SANDOZ CANADA INCORPORATED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ARGATROBAN?
ARGATROBAN 1 MG contains ARGATROBAN : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02548968, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Jan-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ARGATROBAN used for?
Anticoagulant therapy in patients with heparin-induced thrombocytopenia syndrome.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Argatroban cost around the world?
Argatroban is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Iceland publishes a max wholesale; Italy publishes a ex-factory (classe H); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
4 pack listings across 4 brand entries and 3 price bases, refreshed 02 Sep 2026. Ranges span every Argatroban pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Argatroban in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Argatroban — 2 DINs, of which 1 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 2 | 1 | ARGATROBAN | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Concentrate: 250 mg/2.5 mL single-use vials. Ready to use: 50 mg/50 mL single-use vials. |
| Storage | Diluted solutions: 24h at 15-25°C (light) or 48h at 2-8°C (dark). (Note: Specific vial storage not in provided text snippet). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Argatroban |
|---|---|
| ATC code | B01AE03 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02548968 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2548968 |
| Brand name | ARGATROBAN |
| Generic / active ingredient | ARGATROBAN : 1 MG |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | B01AE03 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AE |
| Current status | MARKETED |
| Status date | 29-Jan-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Initial dose 2 mcg/kg/min continuous infusion (adults without hepatic impairment). Adjust to steady-state aPTT 1.5-3.0 times baseline (max 10 mcg/kg/min or 100 seconds).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Active major bleeding; hypersensitivity to the drug or any ingredient; hereditary fructose intolerance.
Warnings and precautions
Hemorrhage risk (monitor hematocrit/BP); use caution in hepatic disease; monitor aPTT; all parenteral anticoagulants must be discontinued before starting.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARGATROBAN | 100 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02243835 |
2 · Same class — other molecules in ATC B01AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dabigatran Etexilate | APO-DABIGATRAN · PRADAXA · TEVA-DABIGATRAN | 8 | 5 | Yes |
| Bivalirudin | ANGIOMAX · BIVALIRUDIN · BIVALIRUDIN FOR INJECTION · BIVALIRUDIN INJECTION | 7 | 5 | Yes |
| Argatroban | ARGATROBAN | 2 | 1 | Yes |
| Lepirudin | REFLUDAN | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AB | Antithrombin · Dalteparin · Danaparoid · Enoxaparin · Heparin · +3 more | 128 | 82 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · +10 more | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ARGATROBAN called?
The same molecule, Argatroban, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Argatra | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.